Compare Ginkgo Bioworks Holdings Inc (DNA) vs Western Digital Corp (WDC) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

Western Digital (WDC) trades at $454.34, up 3.7% in the last 24 hours, with strong earnings beats in recent quarters and a bullish analyst consensus of 72% buy ratings. The stock faces bearish technical signals but benefits from robust AI-driven storage demand, evidenced by 44% revenue growth in Q4 2026 and a net income margin of 72.95% in 2025. Recent news highlights its positioning as a key player in AI infrastructure, though valuation concerns persist.

The outlook for WDC is positive due to sustained AI storage demand and margin expansion, but risks include high valuation multiples and cyclical industry pressures. With a consensus price target of $665.15, upside potential exists, yet investors should monitor competitive threats and earnings sustainability.